企業レポート

Novartis:製薬企業分析レポート

Novartis: Pipeline * Products * Performance * Potential

発行 Espicom Business Intelligence 商品コード 196743
出版日 ページ情報 英文 218 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
Novartis:製薬企業分析レポート Novartis: Pipeline * Products * Performance * Potential
出版日: 2011年03月31日 ページ情報: 英文 218 Pages
概要

当レポートでは、Novartisの企業戦略、製品ポートフォリオ、財務実績や、2009年から2017年までの売上データ予測などを概略下記の構成でお届けいたします。

エグゼクティブサマリー

  • イントロダクション
  • 現在の財務実績
    • 2010年の企業実績
    • セグメント別実績
    • 地域別業績
  • 企業戦略
    • M&A、部門売却
    • 主な提携
    • 研究開発
    • 従業員
  • 製品実績の予測
  • パイプライン分析
    • 廃番となった商品
  • 結論

治療分野への注目

研究開発パイプライン

心血管系および代謝系

  • 上市製品
  • 研究開発プロジェクト

腫瘍/血液学

  • 上市製品
  • 研究開発プロジェクト

神経科

  • 上市製品
  • 研究開発プロジェクト

眼科/皮膚科/泌尿器科

  • 上市製品
  • 研究開発プロジェクト

感染症/移植/免疫学

  • 上市製品
  • 研究開発プロジェクト

関節炎/骨疾患

  • 上市製品
  • 研究開発プロジェクト

呼吸器系

  • 上市製品
  • 研究開発プロジェクト

付録

  • 財務実績
  • 主な提携
  • インフラ
  • 主要な医薬品子会社/ジョイントベンチャー
  • 製品のインデックス

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Abstract

Report Statistics

  • Publication Date: March 31st 2011
  • Total Number of Pages: 218
  • Available Formats: Web, PDF and Paper

Snapshot Novartis - Oncology leads the way in 2010...

... The oncology division lead sales growth in 2010, and with oncology being a major focus for Novartis this trend is set to continue. Novartis has an extensive oncology pipeline, the largest of its therapeutic areas, with promising compounds such as panobinostat and midostaurin, which could prove to be future growth drivers.

We predict that Diovan and Glivec/Gleevec will continue to demonstrate substantial sales growth within the medium term. In addition, the launch and approval of a selection of products which include Exjade (deferasirox), Xolair (omalizumab), Exforge (valsartan+amlodipine) and Lucentis (ranibizumab), should offset the decline in sales of a number of Novartis' strategic products.

In the longer term, as a research-intensive company which has benefited from the Chiron acquisition, Novartis has a strong pharmaceutical pipeline with a total of 147 projects under development.

Forecast Sales of Major Products (2009-2017)

But what' s in the pipeline?

For the full story on Novartis' challenges and opportunities order this important strategic analysis today!

This new strategic report provides a detailed analysis of Novartis' competitive position and prospect for the futures. Using primary source information complemented by original 7-year product forecasts and competitive analysis, the report gives a complete and compelling oversight of the company, its products, pipeline and prospects.

Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.

Table of Contents

Latest Results

EXECUTIVE SUMMARY

  • Introduction
  • Current Financial Position
    • Company Performance 2010
    • Business Segment Performance
    • Geographic Segment Performance
  • Company Strategy
    • Mergers, Acquisitions and Divestitures
    • Key Agreements
      • Discontinued Agreements
    • Research and Development
    • Employees
  • Product Performance Forecasts
  • Pipeline Analysis
    • Discontinued Projects
  • Conclusions

THERAPEUTIC AREA FOCUS

R&D PIPELINE

CARDIOVASCULAR AND METABOLISM

  • Marketed Products
    • Diovan
    • Exforge
    • Galvus
    • Tekturna
  • R&D Projects
    • LCZ696

ONCOLOGY/HAEMATOLOGY

  • Marketed Products
    • Afinitor
    • Exjade
    • Femara
    • Glivec
    • Proleukin
    • Sandostatin
    • Tasigna
    • Zometa
  • R&D Projects
    • AUY299
    • Dovitinib
    • Lucatumumab
    • Midostaurin
    • Opaxio
    • Panobinostat

NEUROSCIENCE

  • Marketed Products
    • Extavia
    • Comtan
    • Exelon
    • Gilenya
  • R&D Projects
    • Valdoxan

OPHTHALMICS/DERMATOLOGY/GASTROINTESTINAL/UROLOGY

  • Marketed Products
    • Elidel
    • Lucentis
    • Wet Age-related Macular Degeneration
    • Visudyne
  • R&D Projects

INFECTIOUS DISEASES/TRANSPLANTATION/IMMUNOLOGY

  • Marketed Products
    • Certican
    • Ixiaro
    • Menveo
    • Sandimmun
    • Sebivo
    • Ilaris
  • R&D Projects

ARTHRITIS/BONE

  • Marketed Products
    • Aclasta
  • R&D Projects
    • Secukinumab

RESPIRATORY

  • Marketed Products
    • Foradil
    • Onbrez
    • Xolair
  • R&D Projects

APPENDIX 1 - FINANCIAL PERFORMANCE

  • Full Year Results 2010

APPENDIX 2 - KEY AGREEMENTS

  • Ablynx
  • Aires Pharmaceuticals
  • Alfacell Corporation
  • Allergan
  • Alnylam Pharmaceuticals
  • AlphaVax Inc.
  • Anadys Pharmaceuticals Inc.
  • Antisoma plc
  • APT Pharmaceuticals
  • Ardana plc
  • Array BioPharma
  • Arrow Therapeutics Ltd.
  • Ascent Therapeutics Inc.
  • Astex Therapeutics Ltd.
  • AstraZeneca
  • Avanir Pharmaceuticals Corporation
  • Avalon Pharmaceuticals
  • Avila Therapeutics
  • Bausch & Lomb Inc.
  • Beijing Med-Pharm Corp.
  • Broad Institute / Harvard University
  • Bayer Schering Pharma
  • Biovail Corporation
  • BTG
  • Celgene Corporation
  • Cell Therapeutics Inc.
  • Cerimon Pharmaceuticals Inc.
  • Clinical Data Inc.
  • CombinatoRx Inc.
  • Conor Medsystems Inc.
  • Cytos Biotechnology AG
  • Cytopia Ltd.
  • Debiopharm SA
  • Dynavax Technologies Corp.
  • Elan Corporation plc
  • Elixir Medical Co.
  • Elixir Pharmaceuticals
  • Emisphere Technologies Inc.
  • Endo Pharmaceuticals
  • Epistem Holdings PLC
  • Evotec AG
  • FORMA Therapeutics Inc.
  • Galapagos NV
  • Genelabs Technologies
  • Genentech
  • Gilead Sciences Inc.
  • Human Genome Sciences (HGS)
  • Idenix Pharmaceuticals Inc.
  • Immusol Incorporated
  • Incyte
  • Infinity Pharmaceuticals Inc.
  • Intercell AG
  • IVAX Corporation
  • Kyorin Pharmaceutical Co., Ltd.
  • Lonza Group Ltd.
  • Meda AB
  • Medarex Inc.
  • Medivir AB
  • Merck KGaA
  • Merck & Co
  • MicroDose Technologies Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Molecular Insight Pharmaceuticals Inc. (MIP)
  • MorphoSys AG
  • MDRNA Inc.
  • Nektar Therapeutics
  • Nuevolution AS
  • Ono Pharmaceutical Co., Ltd.
  • Opexa Therapeutics
  • Orexo AB
  • Orion Corporation
  • Otsuka
  • Paratek Pharmaceuticals
  • Peptimmune Inc.
  • Portola Pharmaceuticals Inc.
  • Proteon Therapeutics Inc.
  • QLT Inc.
  • Quark Pharmaceuticals
  • Radius Health Inc.
  • Regeneron Pharmaceuticals
  • Reliant Pharmaceuticals Inc.
  • Saegis Pharmaceuticals Inc.
  • sanofi-aventis
  • Senju Pharmaceutical Co., Ltd.
  • Servier
  • Sigma-Tau
  • SGX Pharmaceuticals Inc.
  • SkyePharma PLC
  • Takeda
  • Tanox Biosystems Inc./Genentech Inc.
  • TopoTarget AS
  • UCB
  • Valley Forge Pharmaceuticals Inc.
  • Vanda Pharmaceuticals
  • Vectura Group plc/Arakis Ltd.
  • Vernalis plc
  • Xenon Pharmaceuticals Inc.
  • XOMA Ltd.

APPENDIX 3 - INFRASTRUCTURE

  • Research and Development Facilities
  • Manufacturing Facilities

APPENDIX 4 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES

  • Subsidiaries

APPENDIX 5 - PRODUCT INDEX

LIST OF TABLES:

  • Principal Operating Results
  • Research And Development Expenditure By Business Area
  • Sales By Business Area
  • Operating Income By Business Area
  • Total Assets By Business Area
  • Employees By Business Area (Year End)
  • Employees By Geographical Area (Year End)
  • Major Products, Therapeutic Areas and Sales
  • Afinitor Sales by Indication (2009-2017)
  • Tentative ANDA Approvals for Letrozole
  • FDA ANDA Approvals for Octreotide Acetate
  • Tasigna Sales by Indication (2009-2017)
  • Opaxio Sales (2015-2017)
  • Panobinostat Sales by Indication (2011-2017)
  • Interferon Beta-1b Sales by Company (2009-2017)
  • Gilenya Sales (2010-2017)
  • Xolair Sales by Company (2009-2017)
  • Major Pharmaceutical Research & Development Facilities
  • Major Pharmaceutical Production Facilities

LIST OF CHARTS:

  • Capital Expenditure By Business Area, 2010
  • Research And Development Expenditure By Business Area, 2010
  • Sales By Business Area
  • Operating Income By Business Area
  • Sales By Destination
  • Employees By Business Area, 2010
  • Employees By Geographical Area (Year End), 2010
  • Forecast Sales of Major Products (2009-2017)
  • Top Selling Products, 2009
  • Exforge Sales (2009 - 2017)
  • Galvus Sales (2009 - 2017)
  • Afinitor Sales (2009-2017)
  • Exjade Sales (2009-2017)
  • Glivec/Gleevec Sales (2009-2017)
  • Sandostatin Sales (2009-2017)
  • Tasigna Sales (2009-2017)
  • Zometa Sales (2009-2017)
  • Midostaurin Sales (2012-2017)
  • Panobinostat Total Sales (2011-2017)
  • Interferon Beta-1b Sales by Company (2009-2017)
  • Entacapone Sales by Company (2009-2017)
  • Entacapone Sales by Company (2009-2017)
  • Exelon Sales (2009-2017)
  • Gilenya Sales (2010-2017)
  • Lucentis Sales by Company (2009-2017)
  • Final RADICAL outcomes (24 months)
  • Sandimmun/Neoral Sales (2009-2017)
  • Tyzeka Sales (2009-2017)
  • Aclasta/Reclast Sales (2009-2017)
  • Novartis' Sales of Foradil (2009-2017)
  • Onbrez Breezhaler/Arcapta Neohaler Sales (2010-2017)
  • Sales, Costs and Operating Income
  • Profitability and Research Ratios
  • R&D Expenditure and Capital Expenditure
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity
  • Employees and Productivity
Back to Top